drugset / Trial / NCT00262795

Fludarabine or Chlorambucil as First-Line Therapy in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia

NCT00262795

Phase 3 Completed 206 enrolled German CLL Study Group
RandomizedParallel-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy, such as fludarabine and chlorambucil, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. It is not yet known whether fludarabine is more effective than chlorambucil in treating chronic lymphocytic leukemia. PURPOSE: This randomized phase III trial is studying fludarabine to see how well it works as first-line therapy compared to chlorambucil in treating older patients with previously untreated chronic lymphocytic leukemia.

Timeline

Start
2003-09
Primary completion
2005-01
Completion
2005-10

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Chlorambucil Other / unclassified 0.4 mg/kg Oral
Comparator Chlorambucil Other / unclassified 0.8 mg/kg Oral
Subject Fludarabine Small molecule 25 mg/m2 Intravenous